It's been a banner year so far for Insmed Inc. (INSM), with its shares having more than doubled, thanks to Arikayce's surging sales, Brensocatib's ASPEN study success, and TPIP's promising phase II results.
Arikayce, the company's marketed drug, is an antibacterial drug, which secured accelerated approval from the FDA in Sep.2018, for the treatment of a serious lung disease caused by a group of bacteria, Mycobacterium avium complex, in adults who have limited or no alternative treatment options.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.